A Study to Identify Biomarkers of Hypoglycaemia in Patients With Type 2 Diabetes
NCT ID: NCT03102801
Last Updated: 2018-11-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-03-01
Study Completion Date
2018-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Glucose is a sugar carried in the blood stream that body uses for energy. If someone has diabetes, blood glucose level can be erratic, sometimes becoming very low this is called Hypoglycaemia (or a "hypo"), and can happen when blood glucose levels drop below 4 mmol/l.
So far in order to prove that a hypo happened for a patient, blood glucose level can only be measured at time of the hypo and not after it.
In this study we are trying to identify certain chemical substances (biomarkers) in diabetic patients that may be measured in blood tests of the patient up to after 24 hours of the hypo and if we could prove that a hypo has happened we could adjust tablets and or insulin dosage in a way to prevent further hypos.
The study will be conducted in the Diabetes Centre in Hull Royal Infirmary and will involve three visits to the diabetes centre. The study can finish in a week time after the first visit.
Visit 1 is the screening visit to identify eligibility to take part in the study. Visit 2 insulin infusion will be given to make participants blood sugar level fall lower than normal for a short time and corrected quickly afterward. This is a stress for participant's body and should stimulate certain chemicals that we are trying to identify during hypo.
In Visit 3, the main purpose of this visit which is done 24 hours after insulin infusion is to take a blood sample and check how participants is after visit 2.
We will recruit 25 Type 2 Diabetic patients and 25 none diabetics to compare both results.
Both groups should not have ischemic heart disease, underactive thyroid or seizures and on stable dosage of medications.
So far in order to prove that a hypo happened for a patient, blood glucose level can only be measured at time of the hypo and not after it.
In this study we are trying to identify certain chemical substances (biomarkers) in diabetic patients that may be measured in blood tests of the patient up to after 24 hours of the hypo and if we could prove that a hypo has happened we could adjust tablets and or insulin dosage in a way to prevent further hypos.
The study will be conducted in the Diabetes Centre in Hull Royal Infirmary and will involve three visits to the diabetes centre. The study can finish in a week time after the first visit.
Visit 1 is the screening visit to identify eligibility to take part in the study. Visit 2 insulin infusion will be given to make participants blood sugar level fall lower than normal for a short time and corrected quickly afterward. This is a stress for participant's body and should stimulate certain chemicals that we are trying to identify during hypo.
In Visit 3, the main purpose of this visit which is done 24 hours after insulin infusion is to take a blood sample and check how participants is after visit 2.
We will recruit 25 Type 2 Diabetic patients and 25 none diabetics to compare both results.
Both groups should not have ischemic heart disease, underactive thyroid or seizures and on stable dosage of medications.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes
NCT02306681
Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
COMPLETED
Hypoglycemia: Physician and Patient Perspectives
NCT01176656
Type 2 Diabetes Mellitus
Hypoglycemia
COMPLETED
Study of a Primary Care Hypoglycemia Prevention Program
NCT06353217
Diabetes Mellitus
Hypoglycemia
ACTIVE_NOT_RECRUITING
NA
Primary Care Clinicians' Responses to a Hypoglycemia Risk Calculator for Diabetes Mellitus in Ambulatory Care
NCT04177147
Hypoglycemia
Diabetes Mellitus
COMPLETED
NA
Liver Glycogen and Hypoglycemia in Humans
NCT03241706
Hypoglycemia; Iatrogenic
ACTIVE_NOT_RECRUITING
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background information It is well recognised that patients with both type 1 and type 2 diabetes suffering repeated hypoglycaemia are at risk of death and significant morbidity (1). This is of major clinical importance as currently, only the recording of a low blood sugar at the time of hypoglycaemia gives confirmation that a hypoglycaemic event has taken place. There are many instances when the confirmation or exclusion of a hypoglycaemic event would be beneficial.
Landmark studies such as the Diabetes Control and Complications Trial (DCCT) )(2) in type 1 diabetes and the in numerous large studies (UKPDS, ACCORD, ADVANCE, VADT(1, 3-7)) designed to look at whether intensive diabetes control in type 2 diabetes reduced microvascular and macrovascular cardiovascular events, have helped in establishing glycaemic targets which will contribute to preventing the development or worsening of retinopathy, nephropathy and neuropathy. What these studies exemplified was that as glycaemic control became stricter, the risk of hypoglycaemia increased (defined as a blood glucose fall to less than 3.9mmol/l according to American Diabetes Association guidelines)(1, 6, 7). For many patients, the main barrier to achieving optimal glycaemic targets to prevent complications are their increased risks of hypoglycaemia that remains the most feared complication of intensifying diabetes therapy for both patients and their health care professional.
Although hypoglycaemia has traditionally been considered a complication of the treatment for type 1 diabetes, it has recently been recognised as a problem in people with type 2 diabetes particularly those on intensive insulin therapy (8). In type 1 diabetes, patients on average experience two symptomatic events per week and one severe event, the latter of which is responsible for 2-4% of deaths. In type 2 diabetes the risk of a severe hypoglycaemic event is about 7% in the first few years following diagnosis rising to 25% thereafter. There are multiple concerns on the impact that a hypoglycaemic event may have leading to pathological, social and economic consequences. In the ACCORD study, the risk of death was significantly increased in those with one or more episode of severe hypoglycaemia in both the intensive and standard study treatment arms (1, 9). As plasma glucose falls to below 4.0mmol/L, a series of defensive response mechanisms occur, at individualised glycaemic thresholds, to reverse hypoglycaemia including a rise in catecholamine, cortisol and glucagon levels (10). This may lead to hypokalemia, prolonged QT interval, and cardiac arrhythmias (11). It may also lead to increased oxidative stress (12); impaired cardiovascular autonomic function for up to 16 hours afterwards (13); increased inflammatory markers (14); platelet activation (15) and promote vascular damage. These changes might be clinically relevant as hypoglycaemia was associated with cardiac ischemia (chest pain) when 72-h continuous glucose monitoring along with simultaneous cardiac Holter monitoring were performed in people with ischemic heart disease and type 2 diabetes treated with insulin (16). A few studies, in people with type 1 diabetes and healthy controls, suggested an increase in platelet activation with hypoglycaemia (15, 17) emphasising the increased risk that hypoglycaemia may have on cardiovascular events.
All of these changes may therefore result in the generation of biomarkers that may be able to identify the occurrence of a hypoglycaemia event after the blood glucose has reversed to normal or rebound hyperglycaemic levels have resulted. This will be of particular value in hypoglycaemic unawareness, nocturnal hypoglycaemia and events of uncertain aetiology where hypoglycaemia is part of the differential diagnosis.
An ability to determine whether a hypoglycaemic event has occurred through measurement of a biomarker will be of major impact for the confidence of patients and their healthcare providers allowing glycaemic control to be optimised and glycaemic targets to be reached through more stringent diabetes therapeutic treatment regimens.
The ability to identify nocturnal hypoglycaemia will be of particular value in all patients and will circumvent the need for continuous glucose monitoring or enforced waking at 3am to do blood glucose measurements that we currently have to rely on. Identification of biomarkers for hypoglycaemia will be of great value in the elderly population where it is often difficult to determine causes of, for example, feeling non specifically unwell, poor concentration, falls or faints, particularly as there are often multiple morbidities that are being treated at the same time (18).
From an economic perspective it is recognised that hypoglycaemia directly accounts for 95% of endocrine related emergency hospitalisations (19)and it is recognised that severe hypoglycaemia is associated with a total cost of around £2,152 (20) It can then be seen that a new method to determine hypoglycaemia through biomarker determination may help prevent severe hypoglycaemia by earlier recognition and prevent death and morbidity.
One promising biomarker is that of endothelial Microparticles which are heterogeneous population of vesicles playing a relevant role in the pathogenesis of vascular diseases, cancer and metabolic diseases such as diabetes mellitus.
They are released by virtually all cell types by shedding during cell growth, proliferation, activation, apoptosis or senescence processes.(21) Microparticles are consistently present in blood stream (22) they are the main regulators of cell to cell interactions, by carrying specific membrane antigens from their host cells, thereby acting as diffusible vectors in the trancellular exchange of biological information(23).
Microparticles expose membrane proteins of their mother cell for example CD31 is for endothelial cells and a proportion of platelets.(24) CD105,CD106, CD142, CD54, CD62E all Endothelial cells in nature.(25-28) An increased level of circulating Microparticles has been suggested to be one of the procoagulant determinants in patients with type 2 diabetes mellitus (29)Circulating levels of CD31+ (PECAM-1), CD105+, CD106+ and 62E+ endothelial-derived MPs as well as increased concentrations of fibrinogen+, tissue factor, P-selectin+ platelet-derived MPs have been shown to be significantly increased in T2DM patients as compared with non-diabetic controls (25, 26)Indeed, platelets of patients with T2DM are characterised by an hyperreactive phenotype with enhanced adhesion, aggregation, and activation(30), that may contribute to the pathogenesis of atherothrombotic complications(31-33). Therefore, high levels of specific endothelial and platelets Microparticles circulate in the blood of patients with atherosclerotic diseases, and can be used as biomarkers of vascular injury and potential predictors of cardiovascular outcome, especially in diabetic patients(34-37).
Aims and Objectives
Objectives :
Identification and comparison of Microparticles (CD105, CD106, CD31, CD54, CD62E, CD142) following a hypoglycemic event in patients with type 2 diabetes and in subjects without type 2 diabetes.
Study Design Prospective parallel study performed in the Diabetes research centre, Hull Royal Infirmary involving patients with type 2 diabetes and a control group without diabetes
Landmark studies such as the Diabetes Control and Complications Trial (DCCT) )(2) in type 1 diabetes and the in numerous large studies (UKPDS, ACCORD, ADVANCE, VADT(1, 3-7)) designed to look at whether intensive diabetes control in type 2 diabetes reduced microvascular and macrovascular cardiovascular events, have helped in establishing glycaemic targets which will contribute to preventing the development or worsening of retinopathy, nephropathy and neuropathy. What these studies exemplified was that as glycaemic control became stricter, the risk of hypoglycaemia increased (defined as a blood glucose fall to less than 3.9mmol/l according to American Diabetes Association guidelines)(1, 6, 7). For many patients, the main barrier to achieving optimal glycaemic targets to prevent complications are their increased risks of hypoglycaemia that remains the most feared complication of intensifying diabetes therapy for both patients and their health care professional.
Although hypoglycaemia has traditionally been considered a complication of the treatment for type 1 diabetes, it has recently been recognised as a problem in people with type 2 diabetes particularly those on intensive insulin therapy (8). In type 1 diabetes, patients on average experience two symptomatic events per week and one severe event, the latter of which is responsible for 2-4% of deaths. In type 2 diabetes the risk of a severe hypoglycaemic event is about 7% in the first few years following diagnosis rising to 25% thereafter. There are multiple concerns on the impact that a hypoglycaemic event may have leading to pathological, social and economic consequences. In the ACCORD study, the risk of death was significantly increased in those with one or more episode of severe hypoglycaemia in both the intensive and standard study treatment arms (1, 9). As plasma glucose falls to below 4.0mmol/L, a series of defensive response mechanisms occur, at individualised glycaemic thresholds, to reverse hypoglycaemia including a rise in catecholamine, cortisol and glucagon levels (10). This may lead to hypokalemia, prolonged QT interval, and cardiac arrhythmias (11). It may also lead to increased oxidative stress (12); impaired cardiovascular autonomic function for up to 16 hours afterwards (13); increased inflammatory markers (14); platelet activation (15) and promote vascular damage. These changes might be clinically relevant as hypoglycaemia was associated with cardiac ischemia (chest pain) when 72-h continuous glucose monitoring along with simultaneous cardiac Holter monitoring were performed in people with ischemic heart disease and type 2 diabetes treated with insulin (16). A few studies, in people with type 1 diabetes and healthy controls, suggested an increase in platelet activation with hypoglycaemia (15, 17) emphasising the increased risk that hypoglycaemia may have on cardiovascular events.
All of these changes may therefore result in the generation of biomarkers that may be able to identify the occurrence of a hypoglycaemia event after the blood glucose has reversed to normal or rebound hyperglycaemic levels have resulted. This will be of particular value in hypoglycaemic unawareness, nocturnal hypoglycaemia and events of uncertain aetiology where hypoglycaemia is part of the differential diagnosis.
An ability to determine whether a hypoglycaemic event has occurred through measurement of a biomarker will be of major impact for the confidence of patients and their healthcare providers allowing glycaemic control to be optimised and glycaemic targets to be reached through more stringent diabetes therapeutic treatment regimens.
The ability to identify nocturnal hypoglycaemia will be of particular value in all patients and will circumvent the need for continuous glucose monitoring or enforced waking at 3am to do blood glucose measurements that we currently have to rely on. Identification of biomarkers for hypoglycaemia will be of great value in the elderly population where it is often difficult to determine causes of, for example, feeling non specifically unwell, poor concentration, falls or faints, particularly as there are often multiple morbidities that are being treated at the same time (18).
From an economic perspective it is recognised that hypoglycaemia directly accounts for 95% of endocrine related emergency hospitalisations (19)and it is recognised that severe hypoglycaemia is associated with a total cost of around £2,152 (20) It can then be seen that a new method to determine hypoglycaemia through biomarker determination may help prevent severe hypoglycaemia by earlier recognition and prevent death and morbidity.
One promising biomarker is that of endothelial Microparticles which are heterogeneous population of vesicles playing a relevant role in the pathogenesis of vascular diseases, cancer and metabolic diseases such as diabetes mellitus.
They are released by virtually all cell types by shedding during cell growth, proliferation, activation, apoptosis or senescence processes.(21) Microparticles are consistently present in blood stream (22) they are the main regulators of cell to cell interactions, by carrying specific membrane antigens from their host cells, thereby acting as diffusible vectors in the trancellular exchange of biological information(23).
Microparticles expose membrane proteins of their mother cell for example CD31 is for endothelial cells and a proportion of platelets.(24) CD105,CD106, CD142, CD54, CD62E all Endothelial cells in nature.(25-28) An increased level of circulating Microparticles has been suggested to be one of the procoagulant determinants in patients with type 2 diabetes mellitus (29)Circulating levels of CD31+ (PECAM-1), CD105+, CD106+ and 62E+ endothelial-derived MPs as well as increased concentrations of fibrinogen+, tissue factor, P-selectin+ platelet-derived MPs have been shown to be significantly increased in T2DM patients as compared with non-diabetic controls (25, 26)Indeed, platelets of patients with T2DM are characterised by an hyperreactive phenotype with enhanced adhesion, aggregation, and activation(30), that may contribute to the pathogenesis of atherothrombotic complications(31-33). Therefore, high levels of specific endothelial and platelets Microparticles circulate in the blood of patients with atherosclerotic diseases, and can be used as biomarkers of vascular injury and potential predictors of cardiovascular outcome, especially in diabetic patients(34-37).
Aims and Objectives
Objectives :
Identification and comparison of Microparticles (CD105, CD106, CD31, CD54, CD62E, CD142) following a hypoglycemic event in patients with type 2 diabetes and in subjects without type 2 diabetes.
Study Design Prospective parallel study performed in the Diabetes research centre, Hull Royal Infirmary involving patients with type 2 diabetes and a control group without diabetes
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Type 2 Diabetes Mellitus With Hypoglycemia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Type 2 diabetes arm
Both arms will be subjected to Hypoglycaemia and compare results
Group Type
ACTIVE_COMPARATOR
Humulin S
Intervention Type
DRUG
Humulin S used to induce hypoglycaemia
Non diabetics arm
Both arms will be subjected to Hypoglycaemia and compare results
Group Type
ACTIVE_COMPARATOR
Humulin S
Intervention Type
DRUG
Humulin S used to induce hypoglycaemia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Humulin S
Humulin S used to induce hypoglycaemia
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Men and women who are white British or white Europeans between 40 - 70 years of age with type 2 diabetes.
2. Duration of diabetes less than 10 years.
3. Stable dose of medication over the last 3 months.
4. No history of severe hypoglycemic in the preceding 3 months.
5. No hypoglycemic unawareness
6. Able to give informed consent.
1. Men and women who are white British or white Europeans between 40 - 70 years of age.
2. Stable dose of medications in last 3 months.
3. Able to give informed consent.
2. Duration of diabetes less than 10 years.
3. Stable dose of medication over the last 3 months.
4. No history of severe hypoglycemic in the preceding 3 months.
5. No hypoglycemic unawareness
6. Able to give informed consent.
1. Men and women who are white British or white Europeans between 40 - 70 years of age.
2. Stable dose of medications in last 3 months.
3. Able to give informed consent.
Exclusion Criteria
1. Type 1 diabetes.
2. Duration of diabetes of more than 10 years.
3. Patients who are on insulin.
4. HbA1c of ≥ 10%.
5. BMI \<18 or \>50 kg/m2
6. Alcohol excess defined as 14 units per week for a man or a woman. Binge drinking is defined 6 units for a man or women in a single drinking session.
7. Renal impairment with estimated Glomerular Filtration Rate (eGFR\<60 ml/min/1.73 m2).
8. Impaired Liver function tests defined as ALT or AST more than or equal 2.5 times upper limit of the normal.
9. History or presence of malignant neoplasms within the last 5 years( except basal and squamous cell skin cancer and in-situ carcinoma).
10. Psychiatric illness.
11. Any form of gastrointestinal tract surgery.
12. Any medications that can mask Hypoglycaemia such as B-Blockers or Clonidine.
13. Medication that may cause change in glucose metabolism.
14. Patients on any form of steroids in the last six months.
15. Female who is pregnant, breast feeding or intended to become pregnant or of child bearing potential not using adequate contraceptive methods.
16. History of pancreatitis (Acute or Chronic).
17. History of severe hypoglycaemia or hypoglycaemic unawareness.
18. Any disorder which in the opinion of the investigator might jeopardize subject's safety.
19. Contraindications to insulin infusion aiming for hypoglycaemia:
* Ischaemic heart disease.
* Epilepsy or previous history of seizures.
* Drop attacks.
* History of adrenal insufficiency.
* Untreated hypothyroidism.
1. History of diabetes
2. BMI \<18 or \>50 kg/m2
3. HbA1C\>6% (42mmol/mol)
4. Alcohol excess defined as 14 units per week for a man or a women. Binge drinking is defined 6 units for a man or women in a single drinking session.
5. Renal impairment with estimated Glomerular Filtration Rate (eGFR\<60 ml/min/1.73 m2).
6. Impaired Liver function tests defined as ALT or AST more than or equal 2.5 times upper limit of the normal.
7. History or presence of malignant neoplasms within the last 5 years( except basal and squamous cell skin cancer and in-situ carcinoma).
8. Psychiatric illness
9. Female who is pregnant, breast feeding or intended to become pregnant or of child bearing potential not using adequate contraceptive methods.
10. Medication that may cause change in glucose metabolism
11. Any form of gastrointestinal tract surgery.
12. Patient on any form of steroids in the last 6 months.
13. Any disorder which in the opinion of the investigator might jeopardize subject's safety.
14. Contraindications to insulin infusion aiming for hypoglycaemia:
* Ischaemic heart disease.
* Epilepsy or previous history of seizures.
* Drop attacks.
* History of adrenal insufficiency.
* Untreated hypothyroidism.
2. Duration of diabetes of more than 10 years.
3. Patients who are on insulin.
4. HbA1c of ≥ 10%.
5. BMI \<18 or \>50 kg/m2
6. Alcohol excess defined as 14 units per week for a man or a woman. Binge drinking is defined 6 units for a man or women in a single drinking session.
7. Renal impairment with estimated Glomerular Filtration Rate (eGFR\<60 ml/min/1.73 m2).
8. Impaired Liver function tests defined as ALT or AST more than or equal 2.5 times upper limit of the normal.
9. History or presence of malignant neoplasms within the last 5 years( except basal and squamous cell skin cancer and in-situ carcinoma).
10. Psychiatric illness.
11. Any form of gastrointestinal tract surgery.
12. Any medications that can mask Hypoglycaemia such as B-Blockers or Clonidine.
13. Medication that may cause change in glucose metabolism.
14. Patients on any form of steroids in the last six months.
15. Female who is pregnant, breast feeding or intended to become pregnant or of child bearing potential not using adequate contraceptive methods.
16. History of pancreatitis (Acute or Chronic).
17. History of severe hypoglycaemia or hypoglycaemic unawareness.
18. Any disorder which in the opinion of the investigator might jeopardize subject's safety.
19. Contraindications to insulin infusion aiming for hypoglycaemia:
* Ischaemic heart disease.
* Epilepsy or previous history of seizures.
* Drop attacks.
* History of adrenal insufficiency.
* Untreated hypothyroidism.
1. History of diabetes
2. BMI \<18 or \>50 kg/m2
3. HbA1C\>6% (42mmol/mol)
4. Alcohol excess defined as 14 units per week for a man or a women. Binge drinking is defined 6 units for a man or women in a single drinking session.
5. Renal impairment with estimated Glomerular Filtration Rate (eGFR\<60 ml/min/1.73 m2).
6. Impaired Liver function tests defined as ALT or AST more than or equal 2.5 times upper limit of the normal.
7. History or presence of malignant neoplasms within the last 5 years( except basal and squamous cell skin cancer and in-situ carcinoma).
8. Psychiatric illness
9. Female who is pregnant, breast feeding or intended to become pregnant or of child bearing potential not using adequate contraceptive methods.
10. Medication that may cause change in glucose metabolism
11. Any form of gastrointestinal tract surgery.
12. Patient on any form of steroids in the last 6 months.
13. Any disorder which in the opinion of the investigator might jeopardize subject's safety.
14. Contraindications to insulin infusion aiming for hypoglycaemia:
* Ischaemic heart disease.
* Epilepsy or previous history of seizures.
* Drop attacks.
* History of adrenal insufficiency.
* Untreated hypothyroidism.
Minimum Eligible Age
40 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Hull
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thozhukat Sathyapalan
Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hull and east Yorkshire Hospitals NHS Trust
Hull, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United Kingdom
References
Explore related publications, articles, or registry entries linked to this study.
Moin ASM, Nandakumar M, Diboun I, Al-Qaissi A, Sathyapalan T, Atkin SL, Butler AE. Hypoglycemia-induced changes in complement pathways in type 2 diabetes. Atheroscler Plus. 2021 Nov 18;46:35-45. doi: 10.1016/j.athplu.2021.11.002. eCollection 2021 Dec.
Reference Type
DERIVED
Ramanjaneya M, Bettahi I, Pawar K, Halabi NM, Moin ASM, Sathyapalan T, Abou-Samra AB, Atkin SL, Butler AE. MicroRNA Changes Up to 24 h following Induced Hypoglycemia in Type 2 Diabetes. Int J Mol Sci. 2022 Nov 24;23(23):14696. doi: 10.3390/ijms232314696.
Reference Type
DERIVED
Moin ASM, Sathyapalan T, Atkin SL, Butler AE. The severity and duration of Hypoglycemia affect platelet-derived protein responses in Caucasians. Cardiovasc Diabetol. 2022 Oct 6;21(1):202. doi: 10.1186/s12933-022-01639-w.
Reference Type
DERIVED
Ramanjaneya M, Priyanka R, Bensila M, Jerobin J, Pawar K, Sathyapalan T, Abou-Samra AB, Halabi NM, Moin ASM, Atkin SL, Butler AE. MiRNA and associated inflammatory changes from baseline to hypoglycemia in type 2 diabetes. Front Endocrinol (Lausanne). 2022 Aug 9;13:917041. doi: 10.3389/fendo.2022.917041. eCollection 2022.
Reference Type
DERIVED
Nandakumar M, Moin ASM, Ramanjaneya M, Qaissi AA, Sathyapalan T, Atkin SL, Butler AE. Severe iatrogenic hypoglycaemia modulates the fibroblast growth factor protein response. Diabetes Obes Metab. 2022 Aug;24(8):1483-1497. doi: 10.1111/dom.14716. Epub 2022 May 3.
Reference Type
DERIVED
Moin ASM, Nandakumar M, Al-Qaissi A, Sathyapalan T, Atkin SL, Butler AE. Potential Biomarkers to Predict Acute Ischemic Stroke in Type 2 Diabetes. Front Mol Biosci. 2021 Dec 1;8:744459. doi: 10.3389/fmolb.2021.744459. eCollection 2021.
Reference Type
DERIVED
Butler AE, Al-Qaissi A, Sathyapalan T, Atkin SL. Angiopoietin-1: an early biomarker of diabetic nephropathy? J Transl Med. 2021 Oct 13;19(1):427. doi: 10.1186/s12967-021-03105-9. No abstract available.
Reference Type
DERIVED
Atkin AS, Moin ASM, Nandakumar M, Al-Qaissi A, Sathyapalan T, Atkin SL, Butler AE. Impact of severe hypoglycemia on the heat shock and related protein response. Sci Rep. 2021 Aug 23;11(1):17057. doi: 10.1038/s41598-021-96642-8.
Reference Type
DERIVED
Moin ASM, Al-Qaissi A, Sathyapalan T, Atkin SL, Butler AE. Soluble Neuropilin-1 Response to Hypoglycemia in Type 2 Diabetes: Increased Risk or Protection in SARS-CoV-2 Infection? Front Endocrinol (Lausanne). 2021 Jun 23;12:665134. doi: 10.3389/fendo.2021.665134. eCollection 2021.
Reference Type
DERIVED
Moin ASM, Al-Qaissi A, Sathyapalan T, Atkin SL, Butler AE. Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity. Front Endocrinol (Lausanne). 2021 Jun 25;12:658304. doi: 10.3389/fendo.2021.658304. eCollection 2021.
Reference Type
DERIVED
Moin ASM, Kahal H, Al-Qaissi A, Kumar N, Sathyapalan T, Atkin SL, Butler AE. Amyloid-related protein changes associated with dementia differ according to severity of hypoglycemia. BMJ Open Diabetes Res Care. 2021 Apr;9(1):e002211. doi: 10.1136/bmjdrc-2021-002211.
Reference Type
DERIVED
Atkin AS, Moin ASM, Al-Qaissi A, Sathyapalan T, Atkin SL, Butler AE. Plasma heat shock protein response to euglycemia in type 2 diabetes. BMJ Open Diabetes Res Care. 2021 Apr;9(1):e002057. doi: 10.1136/bmjdrc-2020-002057.
Reference Type
DERIVED
Moin ASM, Al-Qaissi A, Sathyapalan T, Atkin SL, Butler AE. Platelet Protein-Related Abnormalities in Response to Acute Hypoglycemia in Type 2 Diabetes. Front Endocrinol (Lausanne). 2021 Mar 30;12:651009. doi: 10.3389/fendo.2021.651009. eCollection 2021.
Reference Type
DERIVED
Moin ASM, Sathyapalan T, Diboun I, Atkin SL, Butler AE. Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19. Sci Rep. 2021 Mar 19;11(1):6428. doi: 10.1038/s41598-021-85760-y.
Reference Type
DERIVED
Moin ASM, Al-Qaissi A, Sathyapalan T, Atkin SL, Butler AE. Do biomarkers of COVID-19 severity simply reflect a stress response in type 2 diabetes: Biomarker response to hypoglycemia. Metabolism. 2021 Jan;114:154417. doi: 10.1016/j.metabol.2020.154417. Epub 2020 Nov 4. No abstract available.
Reference Type
DERIVED
Moin ASM, Sathyapalan T, Atkin SL, Butler AE. Pro-fibrotic M2 macrophage markers may increase the risk for COVID19 in type 2 diabetes with obesity. Metabolism. 2020 Nov;112:154374. doi: 10.1016/j.metabol.2020.154374. Epub 2020 Sep 16. No abstract available.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Version 2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Hypoglycemia Biomarkers to Predict Timing of a Hypoglycemic Event
NCT06652867
COMPLETED
Hypoglycemia in Hospitalized Patients
NCT02228642
COMPLETED
Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM
NCT00515801
COMPLETED
PHASE2/PHASE3
Oral Anti Diabetic Agents in the Hospital
NCT04416269
RECRUITING
PHASE4
Diagnosing and Treating Low Blood Sugar Levels
NCT00001276
RECRUITING
Hypoglycaemia in People With Type 2 Diabetes in Primary Care
NCT02666521
COMPLETED
Hypoglycemia Prevention in High-Risk Type 2 Diabetes Patients
NCT06746714
COMPLETED
NA
Naltrexone and Hypoglycemia in Type 1 Diabetes
NCT01053078
COMPLETED
PHASE1/PHASE2
Glycemic Control in Diabetic Hospitalized Patients
NCT04800861
COMPLETED
Investigating Novel Predictions of Hypoglycemia Occurrence in Real-world Models
NCT04219514
COMPLETED
Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery
NCT01971047
WITHDRAWN
PHASE4
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
NCT01696266
COMPLETED
Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery
NCT01283126
COMPLETED
NA
Achieving Normal Glucose In Hospital Settings
NCT01359241
COMPLETED
NA
Degludec Insulin Use in Critically Ill Patients
NCT06056167
COMPLETED
NA
Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia
NCT01462227
COMPLETED
NA
A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
NCT02230631
COMPLETED
Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA
NCT00920725
COMPLETED
NA
Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)
NCT03608163
TERMINATED
PHASE4
Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes
NCT02866435
COMPLETED
EARLY_PHASE1
Ambulance 'Hypos Can Strike Twice' Study
NCT04243200
COMPLETED
Avoidance of Hyperglycaemia in People With Type 1 Diabetes
NCT04732780
COMPLETED
Naloxone, Hypoglycemia and Exercise
NCT03149770
COMPLETED
PHASE2
Disorders of Systemic Glucose Balance
NCT00006508
COMPLETED
NA
Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia
NCT06178874
COMPLETED
NA